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httpcense.Abstract Background and aim: Hepatitis C virus is a global health problem, and is associated with
various health hazards. This study aimed at evaluation of the pulmonary hazards of hepatitis C
virus infection and its treatment with Pegylated interferon and ribavirin Peg-INF/RBV vs.
untreated patients.
Patients and methods: The study included 100 patients with chronic HCV infection. Patients
were classiﬁed into two groups. Group I; 50 patients who are receiving Peg-IFN/RBV therapy
and Group 2; 50 patients, chronic HCV infection who did not receive Peg-IFN/RBV therapy.
All patients were exposed to full liver work up and a battery of investigations to assess the pulmon-
ary hazards.
Results: Patients receiving Peg-INF/RBV therapy were younger than untreated patients
(P< 0.001). There was no signiﬁcant difference between both groups in their smoking pattern
(P> 0.05). In interferon treated group, interstitial lung disease (ILD), bronchial hyper-reactivity
and chronic cough were signiﬁcantly predominant, while pleural effusion, gastro-esophageal reﬂux
disease (GERD) and pulmonary function test abnormalities showed non signiﬁcant difference
between both groups. There was no relation between the durations of Peg-INF/RBV therapy
and development of pulmonary hazards was noticed.322441.
com (A.e.M. Elgazzar).
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326 S. Elhelaly et al.Conclusions: Treatment of chronic HCV with Peg-INF could result in pulmonary complications;
the most common was bronchial hyperreactivity, chronic cough, restrictive pulmonary dysfunction,
unexplained dyspnea and ILD. While other complications such as pneumonia and pleural effusion
were as common as in untreated patients.
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Hepatitis C virus (HCV) is the most important cause of liver
disease in Egypt [1,2], with the latest anti-HCV antibody prev-
alence of 14.7% [3]. It is a progressive disease that can lead to
cirrhosis, liver failure, hepatocellular carcinoma and death [4].
The currently recommended therapy for chronic HCV is the
combination of Pegylated interferon alpha (Peg-IFN) and
ribavirin (RBV) that proved superior to either standard inter-
feron alpha or ribavirin [5,6].
Over the last decade, emerging clinical data suggest that
chronic HCV infection can lead to multiple direct and indirect
pulmonary complications [7]. Secondary effects of HCV infec-
tion on pulmonary disease are either related to liver cirrhosis
and portal hypertension or to the autoimmune disorders that
are frequently seen in association with chronic HCV infection
[8]. Many case reports of Peg-IFN/RBV-associated pulmonary
complications were recorded [8].
This study tried to estimate HCV related pulmonary com-
plications as well as Peg-IFN/RBV therapy induced pulmon-
ary complications.Patients and methods
This study was carried out at Tropical Medicine and Chest
Departments, Zagazig University Hospitals during the period
from February 2010 to March 2011. All patients signed an in-
formed consent and the study protocol was approved by the
Institution Review Board (IRB).
The study included 100 chronic HCV patients. The
diagnosis of HCV was done by detection of anti-HCV
antibody and conﬁrmed by HCV RNA. Further diagnostic
workup to assess the liver status included; liver function
tests, and liver biopsy (for cases candidate for combination
therapy).
Patients were classiﬁed into two groups:
Group 1: Fifty patients with chronic HCV who are receiving
the standard combination therapy for HCV. They had the
following criteria to be candidate for IFN/RBV therapy:
- Patients aged 18–60 years, normal kidney function tests
(KFTs), thyroid stimulating hormone (TSH).
- Hemoglobin P12 g/dl for men and P11 g/dl for women,
WBCs >3500/mm3, neutrophil count >1500/mm3 and
platelets >85,000/mm3.
- Prothrombin time prolongation <2 s, albumin >3.5 g/dl.
- Positive HCV RNA, HBsAg negative.
- Liver biopsy demonstrating portal ﬁbrosis Pstage F1 and
<stage F4.
Group 2: This group included 50 patients, with chronic
HCV infection who did not receive Peg-IFN/RBV therapy
according to the previous criteria (non eligible).Patients were selected randomly on the basis of their prior-
ity of admission in the group receiving treatment and on the
basis of their priority of asking for medical service. Both
groups were followed up for the same period of time. Any
respiratory complaint was reported.
Exclusion criteria:
(1) Patients with history of a known chest disease before
enrollment in the study.
(2) Patients with systemic illness and patients non HCV
related chronic liver diseases.
All studied patients were subjected to the following:
(1) Thorough medical history and clinical examination.
(2) Laboratory investigations: complete blood count (CBC),
liver and kidney function tests.
(3) Radiological study including:
- Plain chest X-ray: (CXR).
- High resolution computed tomography (HRCT): (only for
those patients with abnormal CXR).
(4) Spirometric pulmonary function testing: (only for those
patients with both normal CXR and HRCT and still
complaining of cough or dyspnea).
The severity of reductions in the forced vital capacity
(FVC) can be graded by the following scheme: [9].
 Mild: 70–79% of predicted.
 Moderate: 60–69% of predicted.
 Moderately severe: 50–59% of predicted.
 Severe: 35–49% of predicted.
 Very severe: less than 35% of predicted.
(1) For detection of airway hyper-responsiveness (Broncho-
provocation test): the change in FEV1 was expressed as
a percentage of predicted value. The criterion taken
for bronchoconstriction was a decline of the FEV1
>15% from the patient own baseline FEV1 [10].
(2) Bronchoalveolar lavage: patients with normal chest
X-ray, HRCT, pulmonary function tests or bron-
cho-provocation test but still experience chest symp-
toms such as cough and/or dyspnea were exposed to
ﬁberoptic bronchoscopy and bronchoalveolar lavage
(BAL) was collected for determination of cellular
pattern.
(3) Diagnostic thoracentesis in case of pleural effusion: pleu-
ral ﬂuid was sent for biochemical analysis.
(4) Diagnosis of gastro-esophageal reﬂux disease (GERD):
GERD can be diagnosed based on GERD question-
naire: it is a patient self-assessment tool which has been
developed to diagnose reﬂux disease. GerdQ question-
naire consisted of six items; four positive predictors of
GERD and two negative predictors.
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(1) Heartburn.
(2) Regurgitation.
(3) Sleep disturbance because of these two reﬂux symptoms.
(4) The use of over-the-counter medication used in addition
to that prescribed.
 The two negative predictors are:
(1) Epigastric pain.
(2) Nausea.
The frequency of the items over the previous week was then
scored 0 for 0 day, 1 for 1 day, 2 for 2–3 days, and 3 for 4–
7 days, giving a total score of 0–18. Patients with a total score
of at least 3 out of possible 6 on the two negative predictors are
those most likely to be impacted by their disease and who may
therefore need more aggressive treatment [11].
Results
Demographic data of the studied patients are represented in
Table 1. Spectrum of the reported respiratory hazards is repre-
sented in Table 2. The present study reported CT evidence of
ILD in ﬁve patients (10%) in the treated group, while in un-
treated group; only one patient (2%) showed CT evidence of
ILD with statistical signiﬁcance (P< 0.05).
N.B: In this study one patient died due to rapidly progres-
sive ILD with pneumothorax, pneumo-mediastinum and se-
vere hypoxemia despite stopping Peg-IFN/RBV therapy and
receiving high dose steroids.
Bronchial hyperreactivity (BHR) was present in 54% of the
treated group (it should be mentioned that; 20% of those pa-
tients were also positive for GERD), while in the untreated
group, 32% of patients were presented by bronchial hyper-
reactivity (18% of those patients were positive for GERD).
BHR was more frequent with the Peg-IFN/RBV therapy
group (P< 0.05).
The percentage of pleural effusion in the treated group was
2% and 2% in the untreated group. Pneumonia was present in
12% of patients in the treated group and in 8% of patients in
the untreated group (P> 0.05) with no signiﬁcant difference
between both groups regarding the occurrence of pleural effu-
sion or pneumonia.
In the treated group, 10 patients (20%) had unexplained
chronic cough; bronchoscopy was done for two of them and
revealed lymphocytic alveolitis, while in the untreated group
only one patient (2%) had unexplained chronic cough
(P< 0.004).
Also, Table 2 showed pulmonary function test pattern in
the two groups; in the treated group, only eight patients
(16%) had restrictive ventilatory dysfunction, while in the un-
treated group six patients (12%) had restrictive ventilatory
dysfunction, without statistically signiﬁcant difference betweenTable 1 Age and sex distribution among all studied patients.
Treated group No. = 50 U
Age (mean ± SD) 42.8 ± 8.3 5
Sex No. % N
Male 35 70 3
Females 15 30 1both groups (P> 0.05). Table 3 showed that gastro-esopha-
geal reﬂux disease was present in 22% of patients in the treated
group, while in the untreated group 30% of patients had
GERD with non signiﬁcant difference (P> 0.05).
Discussion
Chronic HCV infection is associated with multiple extrahe-
patic manifestations including effects on the lung. These in-
clude primary effects on lung function, as well as secondary
effects in the settings of progressive liver disease and drug
treatment for HCV [12,20].
Pegylated interferon-a was approved for the treatment of
patients with chronic HCV who have compensated liver dis-
ease [12,21]. Interferon is associated with multiple pulmonary
complications but severe pulmonary toxicity from therapy
with interferon-a and Pegylated interferon-a is rare (1–5%).
This study showed a signiﬁcant difference between the stud-
ied groups as regards the presence of bronchial hyperreactivity
(54% in the treated group vs. 32% in the untreated group).
This result is in agreement with Bini and Weinshel [13] who
have also proposed that IFN can contribute to the induction
of bronchial hyperreactivity through the activation of Th1
lymphocytes, which results in an increased production of
IFN-c and cytokines.
Moreover Kubo et al. [14] found that analyzing bronchoal-
veolar lavage ﬂuid (BALF) from patients with HCV infection
revealed a signiﬁcant increase in lymphocytes and neutrophils,
or lymphocytes and eosinophils. These inﬂammatory cells can
increase airway responses through releasing mediators such as:
histamine, leukotrienes, platelet activating factor and various
proteases. Also, Kanazawa et al. [15] suggested that the airway
disease may be related to underlying chronic inﬂammation
with emphasis on the possible effects mediated by HCV-spe-
ciﬁc T lymphocytes and latent viral infection.
Such predominance of bronchial hyperreactivity in the trea-
ted group could be explained by the associated neutropenia all
through the course of INF treatment that may predispose to
repeated subclinical viral and/or bacterial infections and con-
sequently bronchial hyperreactivity.
In the current study, the incidence of ILD was signiﬁcantly
higher in the treated group than the untreated group (10% vs.
2%). This result is consistent with Serena et al. [16] who col-
lected 9% [of total cases (25 cases)] developed interstitial pneu-
monitis by IFN therapy for chronic HCV infection.
Several pathophysiological mechanisms have been pro-
posed to explain the lung damage produced by IFN. These
mechanisms were centered on the known immunomodulatory
activity of IFN [17]. Proposed mechanisms for the activity
and pulmonary toxicity associated with IFN include; inhibi-
tion of suppressor T cells, enhancement of cytotoxic T cells,
induction of proinﬂammatory cytokines and exaggeratedntreated group No. = 50 T P-value
3.5 ± 11.4 1.2 0.02
o. % X2
6 72 0.049 >0.05
4 28
Table 2 Frequency of respiratory hazards in all the studied patients.
Treated group No. = 50 Untreated group No. = 50 P-value
No. % No. %
ILD 5 10 1 2 <0.05
Bronchial hyper-reactivity 27 54 16 32 <0.05
Pleural eﬀusion 1 2 1 2 >0.05
Pneumonia 6 12 4 8 >0.05
Restrictive PFT 8 16 6 12 >0.05
Unexplained chronic cough 10 20 1 2 0.004
Table 3 Frequency of gastro-esophageal reﬂux disease in both treated and untreated groups.
Treated group No. = 50 Untreated group No. = 50 X2 P-value
No. % No. %
GERD 11 22 15 30 0.83 0.36
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factor and transforming growth factor-b, leading to lung tissue
ﬁbrosis [17]. Although ribavirin can cause dry cough and dysp-
nea, there were no documented cases of pathologic pulmonary
toxicity due to ribavirin therapy alone [17].
On the other hand, the study shows only one patient with
interstitial lung disease in the untreated group. This result is
in agreement with Ferri et al. [18] who found eight patients
had evidence of ILD out of 300 patients with chronic HCV
infection (2.6%). All patients had different degrees of DLCO
reduction. Lung involvement worsened in two patients slowly
over time and remained stable in ﬁve patients; one patient died
with rapidly progressive respiratory failure. The HCV genome
was demonstrated in the lung biopsy specimen of one of the
eight patients, a ﬁnding that might support a more direct path-
ogenic role for HCV in pulmonary ﬁbrosis.
From the previous debates it can be concluded that patient
susceptibility whether genetic or environmental can contribute
to the development of ILD in chronic HCV patients and treat-
ment by INF can potentiate this susceptibility and express it
into disease appearance, this is evidenced by the development
of the disease at variable durations of the treatment course
and by the appearance of variable degrees of the disease at
the same number of INF injections.
The current study revealed no statistically signiﬁcant differ-
ence between both groups regarding the occurrence of pleural
effusion, one patient in each group (P> 0.05). The occurrence
of pleural effusion with INF treatment was reported by Take-
da et al. [19] who recorded a case of a 54-year-old male patient
treated with interferon for chronic HCV, after 14 days of start-
ing treatment, moderate right pleural effusion was detected.
In the present study, pleural effusion was present in only
one patient in the untreated group, although looked fewer than
expected in chronic advanced HCV patients but this ﬁnding
was due to the repeated paracentesis done to those patients be-
fore admission to the hospital that probably was the cause of
decompensation and the need for admission, or done immedi-
ately after admission due to patient distress.
In this study, there was a signiﬁcant difference between
both groups as regards the presence of GERD (P< 0.05).
In the treated group, GERD was either primary due to directeffect of IFN or it might be secondary to IFN induced depres-
sion, irritability, anxiety, emotional liability which also leads
to poor appetite.
In the untreated group, 15 patients (30%) had GERD and
those who had pleural effusion also were positive GERD
which might be attributed to disturbance in pressure difference
around the lower esophageal sphincter. These ﬁndings were in
agreement with Jones et al. [11]
In this study as regards the presence of pneumonia in the
two groups, there was no statistically signiﬁcant difference
(12% in the treated group vs. 8% in the untreated group,
P> 0.05). Such ﬁnding could be due to the predisposition to
development of pneumonia whether neutropenia in the INF
treatment group or hypoalbuminemia in the untreated group.
The current study showed a signiﬁcant difference between
the studied groups as regards unexplained chronic cough
(20% in the treated group vs. 2% in the untreated group,
P< 0.05) after exclusion of other causes of cough. This result
is in agreement with Dicpinigaitis and Weiner [12] who re-
ported that patients without history of respiratory symptoms
developed chronic cough temporally related to the initiation
of therapy with Pegylated interferon and ribavirin for chronic
hepatitis C infection. Cough resolved within 2–6 weeks after
completion of a 48-week course of therapy.
In conclusion, treatment of chronic HCV with Peg-INF
could result in pulmonary complications; the most common
were bronchial hyperreactivity, chronic cough, restrictive pul-
monary dysfunction and unexplained dyspnea and ILD. While
other complications such as pneumonia and pleural effusion
were as common as in untreated patients.References
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